Inozyme Pharma: Inozyme Pharma is a biotechnology startup that develops new medicines to treat rare disorders of calcification. These diseases are characterized by mineral imbalances, which lead to over calcification of soft tissues and under mineralization of bone. Their focus in on diseases that largely impact infants, children, and young adults. Lead candidate is an enzyme replacement therapy designed to treat calcification disorders of the circulatory system, bone and kidney for which insufficient treatment options currently exist. The firm was founded in 2016 with technology licensed from Yale University that was developed in the lab of Demetrios Braddock.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Other
Listing
Public, USA
Market Cap
500MM - 1B
Website:
Address:
700 Technology Sq
Fl 2
Cambridge, MA 02139

Top 10 Holders of Inozyme Pharma, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
RA Capital Management LLC 8.58 2,003,653 44.08 Stakes 7/28/20
Deerfield Management Company LP 4.92 1,150,299 25.31 Stakes 7/28/20
Rock Springs Capital Management LP 4.57 1,067,884 23.49 Stakes 7/28/20
CHI Advisors LLC 3.60 842,191 18.53 Stakes 7/24/20
Fidelity Management & Research Co. LLC 2.61 609,080 13.40 Funds 7/31/20
The Vanguard Group, Inc. 0.25 56,651 1.25 Funds 8/31/20
CNH Partners LLC 0.00 216 0.00 Funds 7/31/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.